NPPB and pulmonary arterial hypertension: In this cohort of seven patients with CTD-PAH and concomitant ILD, sotatercept demonstrated significant improvements in PVR, eRVSP, 6MWD, WHO Functional Class, NT-proBNP, and supplemental oxygen requirements.